Tolcapone

Limits on what this shows

• Key negative/null findings: Entacapone, tested in parallel in two of the four studies, consistently showed little or no mitochondrial effect at the same or higher concentrations, which argues the effect is tolcapone-specific chemistry (lipophilicity and reactivity at the nitrocatechol C1 position, per Pinto et al.) rather than a generic COMT-inhibitor class effect [5][6].
• At-risk subgroups: None established in humans; all evidence is preclinical/in vitro. The clinical correlate is tolcapone's own boxed hepatotoxicity warning, mechanistically informed by this evidence but graded in the Pharmacokinetic Basis as the drug's known adverse effect, not re-graded here as a separate deficiency finding (Hard Rule 2).

Mechanism

Named (Step 2, mechanism E: mitochondrial interference). Tolcapone uncouples oxidative phosphorylation and inhibits respiratory-chain complexes directly, independent of cytochrome P450 bioactivation [4][5][6].

Population evidence

None; all four studies are drug-specific in vitro/ex vivo (Tier B), not human. Haasio et al. 2002 (Eur J Pharmacol): isolated rat liver mitochondria; tolcapone disrupted membrane potential at concentrations as low as 2.6 micromol/L, comparable to the reference uncoupler 2,4-dinitrophenol, while entacapone had no effect at therapeutic concentrations; with serum proteins present, tolcapone retained only about 10% of its COMT-inhibitory activity versus about 50% for entacapone; tolcapone (50 mg/kg) but not entacapone (400 mg/kg) raised rectal temperature in rats co-dosed with levodopa/carbidopa (p<0.01) [4]. Grünig et al. 2017 (Toxicol In Vitro): human HepaRG hepatocyte-like cells and isolated mouse liver mitochondria; tolcapone's ATP-depletion IC50 was approximately 100±15 micromol/L and cytotoxicity IC50 approximately 333±45 micromol/L, versus no ATP depletion or cytotoxicity for entacapone up to 200 micromol/L; tolcapone inhibited maximal complex I- and complex II-linked oxygen consumption in HepaRG cells and inhibited complexes I, II, and IV in isolated mitochondria (entacapone inhibited only I and IV); both compounds uncoupled oxidative phosphorylation, confirmed by oligomycin-stimulated complex I-linked respiration, tolcapone more potently; the authors conclude tolcapone "is a more potent mitochondrial toxicant than entacapone" [5]. Pinto et al. 2024 (ACS Pharmacol Transl Sci): primary rat hepatocytes, Caco-2 intestinal cells, and HepG2 cells, treated at 1/10/50 micromol/L for 24 hours with Seahorse mitochondrial-bioenergetics assays; concluded tolcapone-induced toxicity "is caused by direct interference with mitochondria that does not depend on bioactivation by P450," with lipophilicity as the key determinant of toxic potential across a series of nitrocatechol analogs [6]. Smith et al. 2003 (Chem Res Toxicol): in vitro hepatocyte metabolism study identifying reactive-intermediate formation as mechanistically relevant to tolcapone's liver toxicity (title and drug-specific design confirmed via Crossref; the journal is paywalled and the full abstract could not be independently retrieved this session) [7].

Counter-evidence held on record

None found contradicting the direction of effect for tolcapone specifically; entacapone's consistent lack of effect across the same assays is the closest counter-evidence, and it argues the finding is drug-specific rather than class-wide. This describes a drug-induced mitochondrial-toxicity mechanism relevant to tolcapone's own known liver-injury risk, not a dietary mitochondrial-nutrient deficiency, and does not support CoQ10, carnitine, riboflavin, or any other "mitochondrial support" supplement. These same four studies also inform the Oxidative stress and ATP production entries below; see Overlap map. Do not count them as additional independent confirmation there.

Limits on what this shows

• Key negative/null findings: None located specific to tolcapone; no human antioxidant-status or oxidative-marker study for tolcapone was found in the channels reached this session.
• At-risk subgroups: None established in humans.

Mechanism

Named (Step 2, mechanism E/I, extended to redox chemistry). Tolcapone's catechol ring is proposed to oxidize to an electrophilic quinone-type reactive intermediate capable of conjugating cellular glutathione and other nucleophiles; independently, the mitochondrial uncoupling described in the Mitochondrial burden entry is a separate route to electron-transport-chain-derived reactive oxygen species [6][7].

Population evidence

None; both sources are Tier B in vitro. Smith et al. 2003: in vitro hepatocyte/microsomal metabolism study identifying reactive intermediate(s) formed from tolcapone, proposed as mechanistically relevant to the drug's hepatotoxicity; bibliographic details (title, authors, journal, volume, pages, year, DOI) confirmed directly via Crossref, but the full abstract is behind an ACS paywall and was not independently retrieved this session [7]. Pinto et al. 2024: the same multi-assay screen described in the Mitochondrial burden entry directly measured intracellular reactive species alongside metabolic, lysosomal, and bioenergetic endpoints in tolcapone-exposed rat hepatocytes, Caco-2, and HepG2 cells; the paper's overall conclusion attributes toxicity to direct mitochondrial interference rather than P450 bioactivation, with lipophilicity and specific nitrocatechol substituents (a C1 carbonyl increasing reactivity; a cyano/double-bond moiety reducing it) governing the toxicity gradient across analogs [6].

Counter-evidence held on record

None found for tolcapone specifically; no drug-specific study was located showing reduced or unchanged oxidative markers. This is a proposed toxicity mechanism contributing to tolcapone's own hepatotoxicity risk, not a measured antioxidant or glutathione deficiency in patients, and does not support antioxidant supplementation, which has no established role in preventing tolcapone-associated liver injury; routine liver-enzyme monitoring per the label is the actual safeguard. Shares its Pinto et al. 2024 source with the Mitochondrial burden and ATP production entries; see Overlap map.

Limits on what this shows

• Key negative/null findings: Entacapone's own label-cited one-year data found no anemia or hemoglobin signal despite the confirmed chelation tendency, suggesting even a confirmed class mechanism may not reach clinical magnitude [8].
• At-risk subgroups: None established for tolcapone. If the mechanism applies at all, patients co-administering oral iron supplements at the same time as tolcapone would be the theoretical at-risk group, by direct analogy to entacapone's own timing-interaction guidance.

Regulatory status

Tolcapone's FDA label makes no statement about iron chelation, serum iron, anemia, or hemoglobin in either direction [1]. Entacapone's FDA label, re-read directly this session, states "Entacapone is a chelator of iron" with "a tendency towards decreasing serum iron concentrations" in controlled trials, though "serum ferritin levels...were not changed" and "there was no difference in rates of anemia or decreased hemoglobin levels" after one year [8].

Mechanism

Class extrapolation (Hard Rule 6), cohort test applied: entacapone (class member) has real Tier A drug-specific evidence; tolcapone (target drug) does not. The chelating moiety, an ortho-catechol/nitrocatechol diol, is structurally shared by both molecules, which is why the mechanism is at least plausible for tolcapone rather than merely assumed from the drug-class label alone. This does not establish that tolcapone chelates iron to the same degree, or at all, in vivo: tolcapone's substantially higher lipophilicity and distinct hepatic handling (see Pharmacokinetic Basis and Mitochondrial burden) mean its disposition differs enough from entacapone's that the chelation finding cannot be assumed to transfer at the same magnitude.

Population evidence

None for tolcapone. For entacapone: the FDA-reviewed controlled-trial dataset cited directly in its own label [8].

Counter-evidence held on record

No tolcapone-specific counter-evidence exists because no tolcapone-specific study exists either way; entacapone's own reassuring one-year anemia/hemoglobin data is the closest available counter-evidence to a severe reading of the shared mechanism. Do not present this as "tolcapone depletes iron." It is an unverified, explicitly labeled class extrapolation from a different drug in the same class, not tolcapone-specific evidence, and does not support iron supplementation. See Overlap map and the Gut microbiome risk entry, which share this same class-extrapolation basis.

Limits on what this shows

• Why no grade: No present mechanism was identified at Step 2: COMT uses Mg2+, not Cu2+, as its catalytic cofactor (the same reasoning that left entacapone's copper entry ungraded in this project's companion review), and tolcapone does not target dopamine-beta-hydroxylase, the copper-dependent enzyme in catecholamine metabolism. No Tier B or Tier C drug-specific or class-level evidence was located, and no circulating consumer claim about tolcapone and copper was found to rebut as white. The dual condition for ungraded (Step 7) is met.

Channels tried

Crossref works API, "tolcapone copper": 8 results returned, all tolcapone reference/pharmacopeial entries (Royal Pharmaceutical Society monograph, two USP monographs, Meyler's Side Effects of Drugs, Encyclopedia of Psychopharmacology, a 2002 Reactions Weekly case note on clozapine/tolcapone), none mentioning copper. A follow-up query combining tolcapone with ceruloplasmin/zinc/magnesium returned a 429 rate-limit response and was not completed. PubMed search-listing page and Europe PMC REST API: both returned repeated 429 rate-limit responses this session and were not usable as additional channels for this category. Semantic Scholar: 429 on the attempts made. OpenAlex bulk search: 429 on the attempts made. DailyMed/FDA label for tolcapone: fetched directly and read in full; no mention of copper, ceruloplasmin, or any trace mineral. Drugs.com: fetched directly; no mineral or supplement claims of any kind. General WebSearch: unavailable (session budget exhausted).

Assessment

Most likely a genuine literature gap, consistent with the mechanism screen (no copper-dependent step in tolcapone's pharmacology) rather than a tooling failure, though the Crossref, PubMed, and Europe PMC blocks mean this should still be re-checked in a future revision if those channels recover.

Limits on what this shows

• Key negative/null findings: None specific to tolcapone; no tolcapone-gut-microbiome study of any kind was located in the channels reached this session.
• At-risk subgroups: None established for tolcapone.

Mechanism

Class extrapolation (Hard Rule 6), cohort test applied and independently re-verified this session: the study's own abstract names only entacapone and loxapine succinate as tested compounds; tolcapone is not named or tested anywhere in it [9]. The mechanism, iron chelation via catechol/nitrocatechol chemistry, is the same one described in the Iron entry and is structurally plausible for tolcapone, but is unverified for it.

Population evidence

None for tolcapone. For entacapone: ex vivo human fecal-community study using quantitative microbiome profiling, long-read metagenomics, stable isotope probing, and single-cell chemical imaging; entacapone complexed and depleted microbiota-accessible iron, suppressing microbial growth that was rescued by replenishing iron, and selected for iron-scavenging taxa carrying antimicrobial-resistance and virulence genes [9].

Counter-evidence held on record

None found; no tolcapone-gut-microbiome data exists in either direction. This is an entacapone-specific, not a tolcapone-specific, finding, carried forward only because the chelating chemistry is structurally shared and clearly labeled as such. It must not be presented to a reader as established tolcapone evidence, and does not support any supplement or probiotic recommendation. See Overlap map; shares its mechanism and comparator source with the Iron entry.

Limits on what this shows

• Key negative/null findings: Entacapone's lack of effect in the same assays, at higher concentrations tested, in both studies [4][5].
• At-risk subgroups: None established in humans; this is cellular/mitochondrial-level in vitro evidence, not a measured whole-body energy or fatigue outcome in tolcapone-treated patients, and must not be presented as one (Hard Rule 2).

Mechanism

Named (Step 2, mechanism E, ATP-synthesis-specific readout). Respiratory-complex inhibition (complexes I, II, and IV in isolated mitochondria) plus uncoupling of oxidative phosphorylation directly reduces ATP-synthesis capacity, measured here as ATP content rather than inferred [4][5].

Population evidence

None; both sources are Tier B. Grünig et al. 2017: tolcapone's ATP-depletion IC50 was approximately 100±15 micromol/L in human HepaRG cells; entacapone caused no ATP depletion up to 200 micromol/L in the same assay [5]. Haasio et al. 2002: isolated rat liver mitochondria lost membrane potential, the proton-motive-force component that drives ATP synthase, at tolcapone concentrations as low as 2.6 micromol/L, with entacapone inactive at therapeutic concentrations [4].

Counter-evidence held on record

None found for tolcapone specifically; entacapone's inactivity in the same assays is the available comparator, not a contradiction of tolcapone's own result. This is a cellular ATP-synthesis-capacity finding tied to tolcapone's hepatotoxicity mechanism, not a validated marker of whole-body energy deficit or "low ATP" in a treated patient, and does not support CoQ10, creatine, or ribose-type "ATP support" supplementation. Shares its source base with Mitochondrial burden (Haasio 2002, Grünig 2017) and, via Grünig 2017 and Pinto 2024, partially with Oxidative stress; see Overlap map. These are not three independent confirmations of three separate effects.

Limits on what this shows

• Why no grade: No mechanism naturally implicates systemic oxygen delivery in tolcapone's own pharmacology beyond the same unverified, already twice-extrapolated chelation-to-anemia hypothesis carried, more directly, by the Iron entry; applying it a second time here would compound speculation rather than add evidence. No tolcapone-specific or class-level (entacapone or tolcapone) study measuring hemoglobin, hematocrit, red-cell mass, arterial oxygenation, or tissue oxygen delivery was located, and tolcapone's own FDA label makes no anemia/hemoglobin statement in either direction (contrast entacapone's label, which does; see Iron entry). No circulating consumer claim about tolcapone and oxygen delivery, "energy," or red blood cells was located to rebut as white. The dual condition for ungraded (Step 7) is met.

Channels tried

Crossref works API, "tolcapone anemia hemoglobin iron": returned results but none matched tolcapone (irrelevant pediatric-anemia and iron-supplementation literature); a follow-up query, "tolcapone hemoglobin anemia hematocrit," was rejected with a 429 rate-limit response and not successfully retried this session. PubMed search-listing page, "tolcapone AND (hemoglobin OR hematocrit OR anemia OR erythropoietin)": returned a 429 rate-limit response on the only attempt made; this host was rate-limited for most of this session. Europe PMC REST API: every attempt this session, across multiple queries and phrasings, returned a 429 rate-limit response and was never successfully read. Semantic Scholar search API: 429 on the one attempt made. OpenAlex: its bulk search endpoint returned 429s on most attempts; its single-record per-PMID/DOI lookup endpoint, which worked reliably elsewhere in this dossier, has no relevant record to look up here because no candidate tolcapone-specific or class-level study was ever identified by title through any channel. DailyMed/FDA structured label for tolcapone: fetched directly and read in full; contains no statement about hemoglobin, hematocrit, anemia, or oxygen delivery in either direction. Drugs.com consumer monograph: fetched directly; no mention of energy, oxygenation, or blood-related claims. General WebSearch: unavailable this session (session-wide search budget exhausted before tolcapone-specific research began).

Assessment

Most likely a genuine literature gap for tolcapone specifically, consistent with the pharmacokinetic prescreen (no renal, hematologic, or absorption mechanism described in tolcapone's own label) and with the absence of any oxygen-delivery finding even for entacapone beyond its own label's reassuring one-year anemia data, which itself does not transfer to tolcapone without the same unverified extrapolation already disclosed in the Iron entry. Revisit if Europe PMC, Semantic Scholar, or a general web search becomes available in a future revision; the channels that were blocked this session, rather than returning a clean zero result, are the ones most worth re-checking first.